Leadership & Board
PAMELA R. CONTAG, PH.D., BENJAMIN C. CARTER, M.B.A, CATHERINE SOHN, PHARM. D., GREGORY T. SCHIFFMAN, M.B.A, CPA, ELONA BAUM, ESQ., OLIVER HOPKINSON, MARK FROHLICH, M.D., BIAO HE, PH.D.
16818
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16818,page-child,parent-pageid-16055,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Leadership & Board

LEADERSHIP

Stephen G. Marcus, M.D., Chief Executive Officer

 

Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.

 

In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a form of leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.

Neil W. Flanzraich, Executive Chairman

 

Neil W. Flanzraich was the Vice Chairman and President of IVAX Corporation until it was sold to Teva Pharmaceutical Industries Limited in 2006. Before that, he served as Senior Vice President and Chief Counsel at Syntex Corporation and a member of its Executive and Operating Committees prior to its sale to Roche in 1994. Mr. Flanzraich was an early investor in Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director. In addition, Mr. Flanzraich is an independent director of Atrium European Real Estate Limited (VSE/Euronext:ATRS), and an expert-in-residence for an entrepreneurship program at Harvard Law School and Harvard Business School.

Juan F. Rodriguez, Chief Financial Officer

 

Juan F. Rodriguez has served as our Chief Financial Officer since November 2014, bringing more than 20 years of financial and business leadership experience to Cantex, the majority of which has been in the life sciences field. Before joining Cantex, Mr. Rodriguez served as Chief Financial Officer at OPKO Health, Inc. (NYSE: OPK). Prior to that he served as a consultant to Cognitec Systems GmbH, a German software developer, and currently serves as the Chairman of Cognitec’s Advisory Board. Prior to that, Mr. Rodriguez was with Kos Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company (which was later acquired by Abbott Laboratories), last serving as Senior Vice President, Controller and Corporate Administration.

BOARD OF DIRECTORS

Neil W. Flanzraich, Executive Chairman

 

Neil W. Flanzraich was the Vice Chairman and President of IVAX Corporation until it was sold to Teva Pharmaceutical Industries Limited in 2006. Before that, he served as Senior Vice President and Chief Counsel at Syntex Corporation and a member of its Executive and Operating Committees prior to its sale to Roche in 1994. Mr. Flanzraich was an early investor in Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director. In addition, Mr. Flanzraich is an independent director of Atrium European Real Estate Limited (VSE/Euronext:ATRS), and an expert-in-residence for an entrepreneurship program at Harvard Law School and Harvard Business School.

Stephen G. Marcus, M.D., Chief Executive Officer

 

Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.

In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a form of leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.

Todd C. Brady, M.D., Ph.D.

 

Todd C. Brady, M.D., Ph.D., a member of our board of directors, is the President and Chief Executive Officer of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and a member of its board of directors. From April 2013 to December 2013, Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he served as a Principal. From 2002 to 2004, Dr. Brady was Senior Director of business development at Aderis Pharmaceuticals, Inc., a late-stage biotechnology company sold to Schwarz Pharma Mfg., Inc. (now UCB, Inc.) (EBR: UCB). Dr. Brady is a member of the board of directors of Evoke Pharma, Inc. (NASDAQ: EVOK), and of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School (and serves on its Board of Visitors), a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.

Christopher A. Kroeger, M.D.

 

Christopher A. Kroeger, M.D., a member of our board of directors, is the Chief Executive Officer of Maplight Therapeutics, Inc. Dr. Kroeger is a partner of The Aurora Funds, Inc, and is a director of CardioFocus, Inc. Dr. Kroeger also serves on the board of the Johns Hopkins Technology Alliance and The University of Maryland Baltimore Commercialization Advisory Board. Dr. Kroeger previously was the Chief Executive Officer of Ovascience, Inc. and of Cardioxyl Pharmaceuticals. He served as a director of The Council for Entrepreneurial Development. Dr. Kroeger holds an M.D. degree from Stanford University School of Medicine, an M.B.A. degree from Harvard Business School, and a B.A. degree in Biology from Harvard University.

Shawn Lu

 

Shawn Lu, a member of our board of directors, is the Chief Financial Officer and a director of Hepalink USA Inc. Mr. Lu has also been a director of Scientific Protein Laboratories LLC, and is a director of Resverlogix Corp. (TSE: RVX), of Quest Pharmatech (CVE: QPT). Mr. Lu holds a Master’s degree in Finance from Queen’s University in Canada, a Master’s degree in Corporate Economic and Business Administration from Zhongnan University of Economic & Law in China, and a B.S. degree in Engineering from Wuhan University of Transportation Technology in China.